Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
News|Articles|May 23, 2008
Prime Therapeutics gets VIPPS stamp of approval
The pharmacy benefit manager Prime Therapeutics announces that it has received VIPPS accreditation.
Advertisement
The pharmacy benefit manager
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
4
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
5